| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CEBPA Mutation Analysis, Extracted DNA (Client 57774)
Test Code36315
CPT Codes
81218
Preferred Specimen
0.03 mL Extracted DNA
Minimum Volume
0.03 mL
Instructions
DNA is to be shipped frozen. Do not thaw. Minimum and absolute minimum volume is 0.03 mL. Ship DNA immediately after extraction is performed. DNA must remain frozen until testing.
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: See Instructions
Refrigerated: Unacceptable
Frozen: See Instructions
Methodology
Next Generation Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 3 days a week. (A.M.). Reports in 3-4 days.
Clinical Significance
The CEBPA gene, a myeloid transcription factor, is mutated
in a subset of acute myeloid leukemia (AML), particularly
those with chromosome analyses showing normal diploid
karyotype Cytogenetically Normal (CN). CN-AML that have
CEBPA mutations show favorable outcome compared to other
groups of CN-AML. Testing for CEBPA mutation, along with
NPM1 (16158 test code) and FLT3 mutations (test code 90574)
is recommended for all patients with CN-AML.
in a subset of acute myeloid leukemia (AML), particularly
those with chromosome analyses showing normal diploid
karyotype Cytogenetically Normal (CN). CN-AML that have
CEBPA mutations show favorable outcome compared to other
groups of CN-AML. Testing for CEBPA mutation, along with
NPM1 (16158 test code) and FLT3 mutations (test code 90574)
is recommended for all patients with CN-AML.
